Pfizer's Expanded TUKYSA Approval Strengthens Its Breast Cancer Turnaround Case
TUKYSA’s expanded FDA approval may strengthen Pfizer’s oncology franchise and support its post-pandemic revenue diversification story.
FDA Approval Expands Enspryng’s Thyroid Eye Disease Opportunity for Roche-Backed Genentech
The FDA approved Enspryng for thyroid eye disease, giving Genentech and Roche a potential new avenue…
Proofpoint's $6.3 Billion Varonis Deal Puts Cybersecurity M&A and Arbitrage in Focus
Proofpoint’s $6.3 billion all-cash deal for Varonis puts the $49.75 offer, merger spreads and cybers…
Potential J&J Orthopedics Spinoff Puts Conglomerate Strategy and Valuation in Focus
A reported J&J plan to spin out its hips-and-knees unit could reshape the valuation and capital-allo…
Galderma’s $1.5 Billion ZO Skin Health Purchase Signals Continued Aesthetics Consolidation
Galderma’s $1.5 billion cash acquisition of ZO Skin Health highlights consolidation in dermatology a…
Labcorp’s $872 Million BioReference Deal Puts Diagnostics M&A in Focus
Labcorp’s agreement to acquire select BioReference assets from OPKO highlights diagnostics consolida…
Tech Rout Drives Flight to Treasurys as Investors Reassess Risk in U.S. Equities
A broad technology sell-off is pushing investors toward Treasury bonds, sending yields lower and sha…
Aquestive’s Anaphylm NDA Resubmission Clears FDA Filing Hurdle, Setting Up AQST Catalyst
Aquestive’s accepted Anaphylm NDA resubmission gives AQST a key regulatory catalyst, with traders wa…
Labcorp’s $872M BioReference Deal Expands Diagnostics Footprint as OPKO Reshapes Portfolio
Labcorp’s proposed BioReference asset deal could expand its diagnostics capacity while giving OPKO H…
Bank of America Faces $1.2 Billion Fine Over Anti-Money-Laundering Failures
A $1.2 billion US government fine puts Bank of America’s compliance controls and regulatory exposure…